Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2014; 20(26): 8351-8363
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8351
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8351
Nonalcoholic fatty liver disease and polycystic ovary syndrome
Evangeline Vassilatou, Endocrine Unit, 2nd Department of Internal Medicine - Propaedeutic, “Attikon” University Hospital, 12462 Athens, Greece
Author contributions: Vassilatou E solely contributed to this paper.
Correspondence to: Evangeline Vassilatou, MD, PhD, Endocrine Unit, 2nd Department of Internal Medicine - Propaedeutic, “Attikon” University Hospital, 1 Rimini st., 12462 Athens, Greece. niadas@hol.gr
Telephone: +30-210-5832584 Fax: +30-210-5832590
Received: October 28, 2013
Revised: February 17, 2014
Accepted: April 15, 2014
Published online: July 14, 2014
Revised: February 17, 2014
Accepted: April 15, 2014
Published online: July 14, 2014
Core Tip
Core tip: Nonalcoholic fatty liver disease (NAFLD) is frequent in patients with polycystic ovary syndrome (PCOS). Obesity and insulin resistance are considered as the main factors related to NAFLD in PCOS. Androgen excess may be an additional contributing factor to the development of NAFLD. Limited data imply that advanced stage of liver disease is possibly more frequent in obese PCOS patients with NAFLD. PCOS patients, particularly obese patients with the metabolic syndrome, should be screened for NAFLD. Long-term follow up studies are needed to clarify clinical implications, appropriate diagnostic evaluation and optimal treatment for PCOS patients with NAFLD.